“
“Background: Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls.

Objective: We examined the effects of a weekly dose of 8400 IU vitamin D(3) on postural

stability, muscle strength, and safety.

Design: In this double-blind trial, subjects aged >= 70 y with serum 25-hydroxyvitamin D [25(OH) D] concentrations Selleck NVP-HSP990 <= 20 but >= 6 ng/mL were randomly assigned to receive a weekly dose of 8400 IU vitamin D(3) (n = 114) or a placebo (n = 112). Mediolateral body sway with eyes open (assessed with the AccuSway(PLUS) platform; Advanced Medical Technology Inc, Watertown, MA) was the primary endpoint. Secondary endpoints included the short physical performance battery (SPPB) and serum 25(OH) D concentrations. An analysis of covariance model was used for treatment comparisons. Safety and tolerability were monitored.

Results: Serum 25(OH) D concentrations rose significantly (from

13.9 to 26.2 ng/mL, P < 0.001) in patients treated with 8400 IU vitamin D(3) but not in patients treated with the placebo. After 16 wk, neither mediolateral sway nor SPPB differed significantly between treatment groups. However, in the post hoc analysis of patients subgrouped by baseline sway (>= AG-014699 nmr 0.46 compared with <0.46 cm), treatment with 8400 IU vitamin D(3) significantly reduced sway compared with treatment with placebo (P = 0.047) in patients with elevated baseline sway but not in patients with normal baseline sway. Adverse experiences and incidences of hypercalcemia, hypercalciuria, and elevated creatinine were similar with both treatments. In patients treated with 8400 IU vitamin D(3), but not in placebo-treated

patients, parathyroid hormone decreased significantly.

Conclusions: Weekly treatment with 8400 IU vitamin D(3) raised 25(OH) D concentrations in elderly, vitamin D-insufficient individuals. Treatment with 8400 IU vitamin D(3) did not reduce mediolateral sway significantly compared with treatment with placebo in this population, although in post hoc analysis, treatment with 8400 IU vitamin D(3) reduced sway in the subgroup of patients who had elevated sway at baseline. Weekly treatment with 8400 IU vitamin D(3) was well tolerated. This trial was registered Sapanisertib chemical structure at clinicaltrials.gov as NCT00242476. Am J Clin Nutr 2010; 91: 985-91.”
“We have developed a technique to fabricate quantum dot (QD) solar cells with direct doping of Si into InAs QDs in GaNAs strain-compensating matrix in order to control the quasi-Fermi level of intermediate QD states. The Si atoms were evenly incorporated into QDs during the assembling stage of growth such that a uniform array of partially filled QDs has been obtained. Nonradiative recombination losses were also reduced by Si doping and a photocurrent increase due to two-step photon absorption was clearly measured at room temperature detected under filtered air-mass 1.5 solar spectrum. (C) 2011 American Institute of Physics.